Thrivent Financial for Lutherans Has $1.99 Million Stock Position in Inari Medical, Inc. (NASDAQ:NARI)

Thrivent Financial for Lutherans cut its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 1.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,916 shares of the company’s stock after selling 435 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Inari Medical were worth $1,987,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NARI. Jennison Associates LLC lifted its holdings in shares of Inari Medical by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after acquiring an additional 186,617 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Inari Medical by 342.9% during the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock valued at $63,922,000 after purchasing an additional 1,200,000 shares during the last quarter. Bamco Inc. NY increased its position in Inari Medical by 29.5% during the 3rd quarter. Bamco Inc. NY now owns 1,006,129 shares of the company’s stock worth $41,493,000 after purchasing an additional 228,977 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Inari Medical by 101.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company’s stock valued at $32,790,000 after purchasing an additional 400,198 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Inari Medical by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 465,962 shares of the company’s stock valued at $23,787,000 after purchasing an additional 11,990 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

Insider Transactions at Inari Medical

In related news, Director William Hoffman sold 200,000 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the sale, the director now owns 238,987 shares in the company, valued at $14,451,543.89. This represents a 45.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.60% of the stock is currently owned by corporate insiders.

Inari Medical Stock Performance

Inari Medical stock opened at $79.97 on Friday. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $79.99. The firm has a 50 day moving average price of $79.87 and a two-hundred day moving average price of $61.32.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Piper Sandler upped their price target on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a report on Tuesday, January 7th. Robert W. Baird reaffirmed a “neutral” rating and issued a $80.00 target price (down previously from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. Baird R W downgraded Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Canaccord Genuity Group restated a “hold” rating and set a $80.00 price target (up from $74.00) on shares of Inari Medical in a report on Tuesday, January 7th. Finally, William Blair reiterated a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Inari Medical currently has an average rating of “Hold” and a consensus price target of $68.00.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.